Refine by
Diabetic Wounds Articles & Analysis
9 news found
Patented Large Area Shockwaves Technology (LAST) provides delivery of low intensity shockwaves - covering whole regions - for ED treatment as well as Wound Healing (Diabetic Foot Ulcers - DFU). Arm mounted applicators free Operator to engage in other tasks during six painless sessions for ED, or about twelve sessions for DFU, treatment of seated patients. ...
Some examples include: Patients with diabetes. People with diabetes may experience impaired wound healing, with an estimated 15% experiencing chronic non-healing foot ulcers. These open wounds may be vulnerable to infection. Proper diabetes wound care could help ward off a ...
Garoufalis is Co-Chair of the Alliance of Wound Care Stakeholders and past President of both the American Podiatric Medical Association and the International Federation of Podiatrists. He is recognized as a Key Opinion Leader on the diabetic foot, lower extremity wound care, limb salvage, podiatric medicine, and surgery. ...
VA Innovation Ecosystem leader recognized for the Initiative to End Diabetic Limb Loss. SOMERVILLE, Mass., June 29, 2021 — Podimetrics, a virtual care management company dedicated to preventing costly and deadly diabetic amputations, congratulates Suzanne Shirley today on winning the Service to Citizen Award in recognition for her leadership and ...
The study: A Non-invasive Focused Extracorporeal Shockwave Therapy System Promotes Increased Tissue Oxygen Saturation in Chronic Wounds in Persons with Diabetes, was published in the American Journal of Nursing Science in May 2021. The study was conducted in a clinical practice setting and concentrated on 15 wounds from 14 patients with a ...
Aurealis Therapeutics, a private clinical-stage biopharmaceutical company developing AUP-16, the three-in-one combination biologic drug for chronic non-healing wounds and regenerative diseases, announced today that the first diabetic foot ulcer (DFU) patient has been dosed with AUP-16. ...
Aurealis Therapeutics, a private biopharmaceutical company developing AUP-16, the three-in-one combination biologic drug for chronic non-healing wounds and regenerative diseases, announced today clinical trial application (CTA) approval of the AUP-16 phase 1 diabetic foot ulcer (DFU) patient trial by the German Health Authority Paul-Ehrlich-Institute. ...
MIRODERM is also derived from decellularized porcine liver and further processed for use in the management of wounds including diabetic foot ulcers, venous ulcers, pressure ulcers, and surgical and trauma wounds. ...
Coloplast"s donation programme Access to Healthcare just signed a contract with the World Diabetes Foundation (WDF) about a new healthcare project in India. The project aims to improve the treatment of diabetic wounds. ...